Akari Therapeutics (AKTX) Capital Expenditures (2016)
Akari Therapeutics (AKTX) posted quarterly Capital Expenditures of $5897.0 for Q2 2016, down 85.99% on a QoQ basis from $42083.0 in Q1 2016.
Akari Therapeutics (AKTX) Capital Expenditures (2016) Analysis & Trends
Akari Therapeutics (AKTX) has reported Capital Expenditures for 1 consecutive years, with $5897.0 the latest figure, recorded in Q2 2016.
- Quarterly Capital Expenditures changed N/A year-over-year to $5897.0 in Q2 2016, while the trailing twelve-month figure through Jun 2016 was $47980.0 (changed N/A YoY) and the FY2017 annual result came in at $36885.0, down 32.63% from the prior year.
- Capital Expenditures fell to $5897.0 in Q2 2016 per AKTX's latest filing, from $42083.0 in the prior quarter.
- Over the last five years, Capital Expenditures for AKTX reached as high as $42083.0 in Q1 2016 and fell as low as $5897.0 in Q2 2016.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Akari Therapeutics | 86.55 Mn | 86.55 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2016 | 5,897.00 |
| Jun 30, 2016 | 5,897.00 |
| Mar 31, 2016 | 42,083.00 |
| Mar 31, 2016 | 42,083.00 |